- \n
- Reported Positive Topline Data from Phase 2 SPRINT Clinical Study of EDP-235, a 3CL Protease Inhibitor in Development as an Oral, Once-Daily Treatment for COVID-19<\/i><\/li>\n
- Strengthened Balance Sheet Through the Sale of 54.5% of Future MAVYRET\u00ae<\/sup>\/MAVIRET\u00ae<\/sup><\/i>Royalties for an Upfront Payment of $200 Million<\/i><\/li>\n
- On Track to Report Phase 1 Data of EDP-323, an L-Protein Inhibitor in Development as an Oral, Once-Daily Treatment for Respiratory Syncytial Virus, in June<\/i><\/li>\n
- Royalty Revenue for the Quarter was $17.8 Million<\/i><\/li>\n<\/ul>\n
WATERTOWN, Mass.–(BUSINESS WIRE<\/a>)–Enanta Pharmaceuticals, Inc.<\/a> (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today reported financial results for its fiscal second quarter ended March 31, 2023.<\/p>\n
\n\u201cAt Enanta, we are focused on transforming the lives of patients with curative therapies, by leveraging our previous successes in the development of small molecules and our deep understanding of virologic diseases,\u201d said Jay R. Luly, Ph.D., President and Chief Executive Officer of Enanta Pharmaceuticals. \u201cThis vision is supported by positive topline data from our SPRINT Phase 2 study announced today. With EDP-235 and Enanta\u2019s entire pipeline, our goal continues to be to develop cures for life-threatening viral infections. Looking ahead, we are also eager to advance our programs in respiratory syncytial virus with an upcoming data readout for EDP-323, our L-protein inhibitor in development as a once-daily oral treatment, next month. Further, the financial flexibility we now have with the additional funding from our royalty monetization allows us to continue to advance our robust pipeline.\u201d<\/p>\n
Fiscal Second Quarter Ended March 31, 2023 Financial Results<\/b><\/p>\n
\nTotal revenue for the three months ended March 31, 2023 was $17.8 million and consisted of royalty revenue from worldwide net sales of AbbVie\u2019s hepatitis C virus (HCV) regimen MAVYRET\u00ae<\/sup>\/MAVIRET\u00ae<\/sup> (glecaprevir\/pibrentasvir), compared to $18.7 million for the three months ended March 31, 2022.<\/p>\n
\nResearch and development expenses totaled $43.5 million for the three months ended March 31, 2023, compared to $42.1 million for the three months ended March 31, 2022. The increase was primarily due to the timing of clinical trial expenses in our virology programs.<\/p>\n
\nGeneral and administrative expenses totaled $13.8 million for the three months ended March 31, 2023, compared to $10.5 million for the three months ended March 31, 2022. The increase was due to increased stock-related compensation expense and legal fees associated with our patent infringement suit against Pfizer.<\/p>\n
\nNet loss for the three months ended March 31, 2023 was $37.7 million, or a loss of $1.79 per diluted common share, compared to a net loss of $33.6 million, or a loss of $1.63 per diluted common share, for the corresponding period in 2022.<\/p>\n
\nEnanta\u2019s cash, cash equivalents and short-term and long-term marketable securities totaled $225.1 million at March 31, 2023, before giving effect to its April 2023 sale of 54.5% of its ongoing MAVYRET\u00ae<\/sup>\/MAVIRET\u00ae<\/sup> royalties from AbbVie for an upfront payment of $200 million from OMERS, one of Canada\u2019s largest defined benefit pension plans. Enanta expects that its current cash, cash equivalents and marketable securities, as well as the royalty sale and Enanta\u2019s continuing portion of cash from future royalty revenue, will be sufficient to meet the anticipated cash requirements of its existing business and development programs into calendar 2026.<\/p>\n
Pipeline Updates<\/b><\/p>\n
COVID-19 (SARS-CoV-2)<\/i><\/b><\/p>\n
- \n
- \nToday, Enanta announced positive topline data from SPRINT (S<\/b>ARS-Cov-2 PR<\/b>otease IN<\/b>hibitor T<\/b>reatment), a double-blind, placebo-controlled Phase 2 clinical trial of EDP-235, the company\u2019s oral, 3CL protease inhibitor, in non-hospitalized, symptomatic adults with mild or moderate COVID-19 who were not at high risk for severe disease. In the trial, EDP-235 met the primary endpoint and was generally safe and well-tolerated. A dose-dependent improvement in symptoms was observed with EDP-235 treatment compared to placebo, which achieved statistical significance (p<0.05) in the 400mg treatment group at multiple time points, starting as early as one day after the first dose. In a prespecified population consisting of patients enrolled within 3 days of symptom onset, a statistically significant improvement was observed with EDP-235 at 400mg at all time points. While no difference was observed in time to improvement of 14 targeted COVID-19 symptoms, an analysis of a subset of these symptoms showed a 2-day shorter time to improvement in patients receiving EDP-235 400mg who were enrolled within 3 days of symptom onset (p<0.01). No effect on virologic endpoints as measured in the nose was detected due to the rapid viral decline in the placebo arm of this highly immunologically-experienced, standard risk population.<\/p>\n<\/li>\n
- \nEnanta will continue to evaluate data from SPRINT and is focusing on partnership opportunities for Phase 3 and on the potential for a different Phase 2 study in acute or long COVID that could further demonstrate the efficacy of EDP-235.<\/p>\n<\/li>\n
- \nEnanta is advancing a research program focused on the discovery and development of inhibitors of the SARS-CoV-2 papain-like protease (PLpro) for the oral treatment of COVID-19. The company continues to optimize inhibitors as it progresses this program forward to select a development candidate.<\/p>\n<\/li>\n<\/ul>\n
Respiratory Syncytial Virus (RSV)<\/i><\/b><\/p>\n
- \n
- \nEnanta is progressing a broad clinical program, aimed at targeting populations at high-risk for RSV, and is evaluating EDP-938, an N-protein inhibitor, with three ongoing clinical trials. EDP-938 is supported by data from a previous clinical challenge study showing that the compound significantly inhibited replication of RSV, the only published study to show such an effect for an N-inhibitor. EDP-938 also has a favorable and consistent safety profile.<\/p>\n
- \n
- \nMultiple ongoing studies include RSVPEDs, a Phase 2 randomized, double-blind, placebo-controlled study in hospitalized and non-hospitalized pediatric RSV patients; RSVHR, a Phase 2b randomized, double-blind, placebo-controlled study in adults with acute RSV infection who are at high risk of complications, including the elderly and\/or those with congestive heart failure, chronic obstructive pulmonary disease or asthma; and RSVTx, a Phase 2b, randomized, double-blind, placebo-controlled study in adult hematopoietic cell transplant recipients with acute RSV infection and symptoms of upper respiratory tract infection.<\/p>\n<\/li>\n
- \nThese three studies are expected to continue through 2023. Enanta is monitoring RSV epidemiology to determine the impact on trial enrollment and timing for data readouts.<\/p>\n<\/li>\n<\/ul>\n<\/li>\n
- \nEnanta is on track to report topline Phase 1 data in June from its ongoing study of EDP-323, a novel, oral, direct-acting antiviral selectively targeting the RSV L-protein. This double-blind, placebo-controlled, first-in-human study is designed to enroll healthy subjects to assess EDP-323\u2019s safety, tolerability, and pharmacokinetics (PK). EDP-323 has the potential to be used alone or in combination with EDP-938 to potentially broaden the addressable patient populations or the treatment window.<\/p>\n
- \n
- \nIn April, at ECCMID, Enanta reported preclinical data highlighting EDP-323\u2019s favorable preclinical PK properties, excellent bioavailability with low plasma clearance, and favorable target tissue distribution, supporting a once-daily, oral-dosing regimen for RSV.<\/p>\n<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n
Human Metapneumovirus (hMPV)\/RSV<\/i><\/b><\/p>\n
- \n
- \nEnanta\u2019s research program targeting both hMPV and RSV with a single agent, which the company refers to as a dual inhibitor, is ongoing. In preclinical studies, Enanta\u2019s prototype dual inhibitor maintained nanomolar activity against multiple genotypes and strains of hMPV and RSV in a range of cell types. Further, the dual inhibitor potently inhibited replication of both hMPV and RSV in a dose-dependent manner in mouse models of the respective viruses, demonstrating significant reductions in viral load of each virus. Enanta expects to select a dual hMPV\/RSV inhibitor clinical candidate in the fourth quarter of 2023.<\/p>\n<\/li>\n<\/ul>\n
Hepatitis B Virus (HBV)<\/i><\/b><\/p>\n
- \n
- \nEnanta remains focused on identifying additional compounds externally with different mechanisms of action to combine with EDP-514, its potent core inhibitor, and a nucleoside reverse transcriptase inhibitor. EDP-514 has displayed a good safety profile and robust antiviral activity in multiple HBV patient populations, with significant declines in HBV DNA among the best published to date for core inhibitors.<\/p>\n<\/li>\n<\/ul>\n
Corporate<\/b><\/p>\n
- \n
- \nIn April, Enanta strengthened its balance sheet with the sale to OMERS of 54.5% of Enanta\u2019s future royalty payments from AbbVie Inc. on worldwide sales of MAVYRET\/MAVIRET. The upfront purchase price paid to Enanta was $200 million. OMERS right to receive royalty payments is based on net sales of the product beginning in July 2023 through June 2032, with total payments capped at 1.42 times the purchase price. Enanta\u2019s retains 45.5% of all royalties until the cap is hit, at which point 100% of all further royalties revert to Enanta.<\/p>\n<\/li>\n<\/ul>\n
Upcoming Events and Presentations<\/b><\/p>\n
- \n
- \nJMP Securities Life Sciences Conference \u2013 May 16, 2023<\/p>\n<\/li>\n
- \nRBC Capital Markets Global Healthcare Conference \u2013 May 17, 2023<\/p>\n<\/li>\n
- \nJefferies Global Healthcare Conference \u2013 June 7-9, 2023<\/p>\n<\/li>\n
- \nEnanta plans to issue its fiscal third quarter 2023 press release, and hold a conference call regarding those results, on August 7, 2023.<\/p>\n<\/li>\n<\/ul>\n
Conference Call and Webcast Information<\/b><\/p>\n
\nEnanta will host a conference call and webcast today at 4:30 p.m. ET. The live webcast can be accessed under “Events & Presentations” in the investors section of Enanta\u2019s website. To join by phone, participants can register for the call here<\/a>. It is recommended that participants register a minimum of 15 minutes before the call. Once registered, participants will receive an email with the dial-in information. The archived webcast will be available on Enanta\u2019s website for approximately 30 days following the event.<\/p>\n
About Enanta Pharmaceuticals, Inc.<\/b><\/p>\n
\nEnanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for the treatment of viral infections. Enanta\u2019s research and development programs include clinical candidates for the following disease targets: respiratory syncytial virus (RSV), SARS-CoV-2 (COVID-19) and hepatitis B virus (HBV). Enanta is also conducting research on a single agent targeting both RSV and human metapneumovirus (hMPV).<\/p>\n
\nEnanta receives royalties from hepatitis C virus (HCV) products developed under its collaboration with AbbVie. Glecaprevir, a protease inhibitor discovered by Enanta, is part of one of the leading treatment regimens for curing chronic HCV infection and is sold by AbbVie in numerous countries under the tradenames MAVYRET\u00ae<\/sup> (U.S.) and MAVIRET\u00ae<\/sup> (ex-U.S.) (glecaprevir\/pibrentasvir). Please visit www.enanta.com<\/a> for more information.<\/p>\n
FORWARD LOOKING STATEMENTS<\/b><\/p>\n
\nThis press release contains forward-looking statements, including statements with respect to the prospects for advancement of Enanta\u2019s clinical programs in RSV, SARS-CoV-2 and HBV and its preclinical dual-inhibitor program in hMPV\/RSV. Statements that are not historical facts are based on management\u2019s current expectations, estimates, forecasts and projections about Enanta\u2019s business and the industry in which it operates and management\u2019s beliefs and assumptions. The statements contained in this release are not guarantees of future performance and involve certain risks, uncertainties and assumptions, which are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed in such forward-looking statements. Important factors and risks that may affect actual results include: the impact of development, regulatory and marketing efforts of others with respect to competitive treatments for RSV, SARS-CoV-2 and HBV; the discovery and development risks of Enanta\u2019s programs in RSV, SARS-CoV-2, HBV and hMPV; the competitive impact of development, regulatory and marketing efforts of others in those disease areas; any continuing impact of the COVID-19 pandemic on business operations and clinical trials; Enanta\u2019s lack of clinical development experience; Enanta\u2019s need to attract and retain senior management and key research and development personnel; Enanta\u2019s need to obtain and maintain patent protection for its product candidates and avoid potential infringement of the intellectual property rights of others; and other risk factors described or referred to in \u201cRisk Factors\u201d in Enanta\u2019s Form 10-K for the fiscal year ended September 30, 2022, and any other periodic reports filed more recently with the Securities and Exchange Commission. Enanta cautions investors not to place undue reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this release, and Enanta undertakes no obligation to update or revise these statements, except as may be required by law.<\/p>\n
\n
\n ENANTA PHARMACEUTICALS, INC.<\/b><\/td>\n<\/tr>\n \n CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS<\/b><\/td>\n<\/tr>\n \n \n UNAUDITED<\/b><\/p>\n
(in thousands, except per share amounts)<\/b><\/p>\n<\/td>\n<\/tr>\n
\n \n \n \n \n \n \n \n \n \u00a0<\/td>\n<\/tr>\n \n \n \n \n \n \n \n \n \n \u00a0<\/td>\n<\/tr>\n \n \n \n Three Months Ended<\/b><\/td>\n \n Six Months Ended<\/b><\/td>\n<\/tr>\n \n \n \n March 31,<\/b><\/td>\n \n March 31,<\/b><\/td>\n<\/tr>\n \n \n \n \n \n\u00a0<\/p>\n<\/td>\n
\n 2023<\/b><\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n 2022<\/b><\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n 2023<\/b><\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n 2022<\/b><\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n
\n \n \n \n \n \n \n \n \n \u00a0<\/td>\n<\/tr>\n \n Revenue<\/td>\n \n \n \n$<\/p>\n<\/td>\n
\n \n17,795<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n
\n \n \n$<\/p>\n<\/td>\n
\n \n18,716<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n
\n \n \n$<\/p>\n<\/td>\n
\n \n41,380<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n
\n \n \n$<\/p>\n<\/td>\n
\n \n46,364<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n
\n Operating expenses<\/td>\n \n \n \n \n \n \n \n <\/tr>\n \n Research and development<\/td>\n \n \n \n\u00a0<\/p>\n<\/td>\n
\n \n43,468<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n42,087<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n84,370<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n90,636<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n
\n General and administrative<\/td>\n \n \n \n\u00a0<\/p>\n<\/td>\n
\n \n13,778<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n10,476<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n26,474<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n19,984<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n
\n Total operating expenses<\/td>\n \n \n \n\u00a0<\/p>\n<\/td>\n
\n \n57,246<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n52,563<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n110,844<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n110,620<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n
\n Loss from operations<\/td>\n \n \n \n\u00a0<\/p>\n<\/td>\n
\n \n(39,451<\/p>\n<\/td>\n
\n \n)<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n(33,847<\/p>\n<\/td>\n
\n \n)<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n(69,464<\/p>\n<\/td>\n
\n \n)<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n(64,256<\/p>\n<\/td>\n
\n \n)<\/p>\n<\/td>\n<\/tr>\n
\n Other income, net<\/td>\n \n \n \n\u00a0<\/p>\n<\/td>\n
\n \n1,837<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n255<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n2,830<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n549<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n
\n Loss before income taxes<\/td>\n \n \n \n\u00a0<\/p>\n<\/td>\n
\n \n(37,614<\/p>\n<\/td>\n
\n \n)<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n(33,592<\/p>\n<\/td>\n
\n \n)<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n(66,634<\/p>\n<\/td>\n
\n \n)<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n(63,707<\/p>\n<\/td>\n
\n \n)<\/p>\n<\/td>\n<\/tr>\n
\n Income tax expense<\/td>\n \n \n \n\u00a0<\/p>\n<\/td>\n
\n \n(44<\/p>\n<\/td>\n
\n \n)<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n\u2014<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n(10<\/p>\n<\/td>\n
\n \n)<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n\u2014<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n
\n Net loss<\/td>\n \n \n \n$<\/p>\n<\/td>\n
\n \n(37,658<\/p>\n<\/td>\n
\n \n)<\/p>\n<\/td>\n
\n \n \n$<\/p>\n<\/td>\n
\n \n(33,592<\/p>\n<\/td>\n
\n \n)<\/p>\n<\/td>\n
\n \n \n$<\/p>\n<\/td>\n
\n \n(66,644<\/p>\n<\/td>\n
\n \n)<\/p>\n<\/td>\n
\n \n \n$<\/p>\n<\/td>\n
\n \n(63,707<\/p>\n<\/td>\n
\n \n)<\/p>\n<\/td>\n<\/tr>\n
\n Net loss per share<\/td>\n \n \n \n \n \n \n \n <\/tr>\n \n Basic<\/td>\n \n \n \n$<\/p>\n<\/td>\n
\n \n(1.79<\/p>\n<\/td>\n
\n \n)<\/p>\n<\/td>\n
\n \n \n$<\/p>\n<\/td>\n
\n \n(1.63<\/p>\n<\/td>\n
\n \n)<\/p>\n<\/td>\n
\n \n \n$<\/p>\n<\/td>\n
\n \n(3.19<\/p>\n<\/td>\n
\n \n)<\/p>\n<\/td>\n
\n \n \n$<\/p>\n<\/td>\n
\n \n(3.11<\/p>\n<\/td>\n
\n \n)<\/p>\n<\/td>\n<\/tr>\n
\n Diluted<\/td>\n \n \n \n$<\/p>\n<\/td>\n
\n \n(1.79<\/p>\n<\/td>\n
\n \n)<\/p>\n<\/td>\n
\n \n \n$<\/p>\n<\/td>\n
\n \n(1.63<\/p>\n<\/td>\n
\n \n)<\/p>\n<\/td>\n
\n \n \n$<\/p>\n<\/td>\n
\n \n(3.19<\/p>\n<\/td>\n
\n \n)<\/p>\n<\/td>\n
\n \n \n$<\/p>\n<\/td>\n
\n \n(3.11<\/p>\n<\/td>\n
\n \n)<\/p>\n<\/td>\n<\/tr>\n
\n Weighted average common shares outstanding<\/td>\n \n \n \n \n \n \n \n <\/tr>\n \n Basic<\/td>\n \n \n \n\u00a0<\/p>\n<\/td>\n
\n \n21,035<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n20,551<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n20,882<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n20,473<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n
\n Diluted<\/td>\n \n \n \n\u00a0<\/p>\n<\/td>\n
\n \n21,035<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n20,551<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n20,882<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n20,473<\/p>\n<\/td>\n
\n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n<\/table>\n
\n
\n ENANTA PHARMACEUTICALS, INC.<\/b><\/td>\n<\/tr>\n \n CONDENSED CONSOLIDATED BALANCE SHEETS<\/b><\/td>\n<\/tr>\n \n \n UNAUDITED<\/b><\/p>\n
(in thousands)<\/b><\/p>\n<\/td>\n<\/tr>\n
\n \n \n \n \n \u00a0<\/td>\n<\/tr>\n \n \n \n March 31,<\/b><\/td>\n \n September 30,<\/b><\/td>\n<\/tr>\n \n \n \n \n 2023 <\/b><\/p>\n<\/td>\n
\n \n 2022 <\/b><\/p>\n<\/td>\n<\/tr>\n
\n Assets<\/td>\n \n \n \n <\/tr>\n \n Current assets<\/td>\n \n \n \n <\/tr>\n \n Cash and cash equivalents<\/td>\n \n \n \n$<\/p>\n<\/td>\n
\n \n73,178<\/p>\n<\/td>\n
\n \n \n$<\/p>\n<\/td>\n
\n \n43,994<\/p>\n<\/td>\n<\/tr>\n
\n Short-term marketable securities<\/td>\n \n \n \n\u00a0<\/p>\n<\/td>\n
\n \n136,906<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n205,238<\/p>\n<\/td>\n<\/tr>\n
\n Accounts receivable<\/td>\n \n \n \n\u00a0<\/p>\n<\/td>\n
\n \n17,795<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n20,318<\/p>\n<\/td>\n<\/tr>\n
\n Prepaid expenses and other current assets<\/td>\n \n \n \n\u00a0<\/p>\n<\/td>\n
\n \n14,484<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n13,445<\/p>\n<\/td>\n<\/tr>\n
\n Income tax receivable<\/td>\n \n \n \n\u00a0<\/p>\n<\/td>\n
\n \n28,774<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n28,718<\/p>\n<\/td>\n<\/tr>\n
\n Total current assets<\/td>\n \n \n \n\u00a0<\/p>\n<\/td>\n
\n \n271,137<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n311,713<\/p>\n<\/td>\n<\/tr>\n
\n Long-term marketable securities<\/td>\n \n \n \n\u00a0<\/p>\n<\/td>\n
\n \n15,040<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n29,285<\/p>\n<\/td>\n<\/tr>\n
\n Property and equipment, net<\/td>\n \n \n \n\u00a0<\/p>\n<\/td>\n
\n \n11,050<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n6,173<\/p>\n<\/td>\n<\/tr>\n
\n Operating lease, right-of-use assets<\/td>\n \n \n \n\u00a0<\/p>\n<\/td>\n
\n \n24,554<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n23,575<\/p>\n<\/td>\n<\/tr>\n
\n Restricted cash<\/td>\n \n \n \n\u00a0<\/p>\n<\/td>\n
\n \n3,968<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n3,968<\/p>\n<\/td>\n<\/tr>\n
\n Other long-term assets<\/td>\n \n \n \n\u00a0<\/p>\n<\/td>\n
\n \n696<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n696<\/p>\n<\/td>\n<\/tr>\n
\n Total assets<\/td>\n \n \n \n$<\/p>\n<\/td>\n
\n \n326,445<\/p>\n<\/td>\n
\n \n \n$<\/p>\n<\/td>\n
\n \n375,410<\/p>\n<\/td>\n<\/tr>\n
\n Liabilities and Stockholders’ Equity<\/td>\n \n \n \n <\/tr>\n \n Current liabilities<\/td>\n \n \n \n <\/tr>\n \n Accounts payable<\/td>\n \n \n \n$<\/p>\n<\/td>\n
\n \n11,761<\/p>\n<\/td>\n
\n \n \n$<\/p>\n<\/td>\n
\n \n6,000<\/p>\n<\/td>\n<\/tr>\n
\n Accrued expenses and other current liabilities<\/td>\n \n \n \n\u00a0<\/p>\n<\/td>\n
\n \n15,482<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n20,936<\/p>\n<\/td>\n<\/tr>\n
\n Operating lease liabilities<\/td>\n \n \n \n\u00a0<\/p>\n<\/td>\n
\n \n4,923<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n2,891<\/p>\n<\/td>\n<\/tr>\n
\n Total current liabilities<\/td>\n \n \n \n\u00a0<\/p>\n<\/td>\n
\n \n32,166<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n29,827<\/p>\n<\/td>\n<\/tr>\n
\n Operating lease liabilities, net of current portion<\/td>\n \n \n \n\u00a0<\/p>\n<\/td>\n
\n \n23,073<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n22,372<\/p>\n<\/td>\n<\/tr>\n
\n Series 1 nonconvertible preferred stock<\/td>\n \n \n \n\u00a0<\/p>\n<\/td>\n
\n \n1,423<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n1,423<\/p>\n<\/td>\n<\/tr>\n
\n Other long-term liabilities<\/td>\n \n \n \n\u00a0<\/p>\n<\/td>\n
\n \n408<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n454<\/p>\n<\/td>\n<\/tr>\n
\n Total liabilities<\/td>\n \n \n \n\u00a0<\/p>\n<\/td>\n
\n \n57,070<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n54,076<\/p>\n<\/td>\n<\/tr>\n
\n Total stockholders’ equity<\/td>\n \n \n \n\u00a0<\/p>\n<\/td>\n
\n \n269,375<\/p>\n<\/td>\n
\n \n \n\u00a0<\/p>\n<\/td>\n
\n \n321,334<\/p>\n<\/td>\n<\/tr>\n
\n Total liabilities and stockholders’ equity<\/td>\n \n \n \n$<\/p>\n<\/td>\n
\n \n326,445<\/p>\n<\/td>\n
\n \n \n$<\/p>\n<\/td>\n
\n \n375,410<\/p>\n<\/td>\n<\/tr>\n<\/table>\n
\n\u00a0<\/p>\n
<\/p>\n
View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20230508005587\/en\/<\/a><\/span><\/p>\n
Media and Investors Contact:
\n<\/b>
Jennifer Viera
\n
617-744-3848
\n
jviera@enanta.com<\/a><\/p>\nKEYWORDS:<\/b> Massachusetts United States North America<\/p>\n
INDUSTRY KEYWORDS:<\/b> Health Infectious Diseases Clinical Trials Research Science Pharmaceutical Biotechnology<\/p>\n
- \nIn April, Enanta strengthened its balance sheet with the sale to OMERS of 54.5% of Enanta\u2019s future royalty payments from AbbVie Inc. on worldwide sales of MAVYRET\/MAVIRET. The upfront purchase price paid to Enanta was $200 million. OMERS right to receive royalty payments is based on net sales of the product beginning in July 2023 through June 2032, with total payments capped at 1.42 times the purchase price. Enanta\u2019s retains 45.5% of all royalties until the cap is hit, at which point 100% of all further royalties revert to Enanta.<\/p>\n<\/li>\n<\/ul>\n
- \nEnanta remains focused on identifying additional compounds externally with different mechanisms of action to combine with EDP-514, its potent core inhibitor, and a nucleoside reverse transcriptase inhibitor. EDP-514 has displayed a good safety profile and robust antiviral activity in multiple HBV patient populations, with significant declines in HBV DNA among the best published to date for core inhibitors.<\/p>\n<\/li>\n<\/ul>\n
- \nEnanta\u2019s research program targeting both hMPV and RSV with a single agent, which the company refers to as a dual inhibitor, is ongoing. In preclinical studies, Enanta\u2019s prototype dual inhibitor maintained nanomolar activity against multiple genotypes and strains of hMPV and RSV in a range of cell types. Further, the dual inhibitor potently inhibited replication of both hMPV and RSV in a dose-dependent manner in mouse models of the respective viruses, demonstrating significant reductions in viral load of each virus. Enanta expects to select a dual hMPV\/RSV inhibitor clinical candidate in the fourth quarter of 2023.<\/p>\n<\/li>\n<\/ul>\n
- \nIn April, at ECCMID, Enanta reported preclinical data highlighting EDP-323\u2019s favorable preclinical PK properties, excellent bioavailability with low plasma clearance, and favorable target tissue distribution, supporting a once-daily, oral-dosing regimen for RSV.<\/p>\n<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n
- Strengthened Balance Sheet Through the Sale of 54.5% of Future MAVYRET\u00ae<\/sup>\/MAVIRET\u00ae<\/sup><\/i>Royalties for an Upfront Payment of $200 Million<\/i><\/li>\n
![\"Logo\"](\"https:\/\/mms.businesswire.com\/media\/20230508005587\/en\/1475183\/3\/Enanta_RGB.jpg\")
<\/td>\n<\/tr>\n